The FDA has added a boxed warning, its most serious designation, to Copaxone and Glatopa due to the risk of anaphylaxis, a rare but serious allergic reaction. This severe reaction can occur at any ...

The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...

FDA adds boxed warning to Teva's Copaxone and generic versions after serious allergic reactions, including anaphylaxis that ...

UBS raised the firm’s price target on Teva (TEVA) to $30 from $28 and keeps a Buy rating on the shares. Teva, one of the firm’s top picks for ...

Patients should stop taking glatiramer acetate and seek immediate medical attention by going to an emergency room or calling ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

Recent news highlights include Hong Kong shareholders rejecting Fosun's buyout of Henlius Biotech, Abbott focusing on glucose monitors amidst currency woes, FDA warning on multiple sclerosis drugs, ...

Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated ...

Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.

The US Food and Drug Administration (FDA) is warning about the risk of a rare but serious allergic reaction with the medicine ...